The development is clear. Bayer has sold its blood plasma division a few years ago and focuses on recombinant raw material. Interesting detail is that Pharming is working with the US Army on a recombinant fibrin tissue sealant. Such sealants need Human Fibrin and Thrombin. Existing sealants are far too expensive for widespread use due to the costs of the plasma derived components. However, once much cheaper, recombinant components are available, this market may grow very fast. Zymogenetics can soon deliver rhThrombin. Then it will be a question of Pharming getting its rhFibrinogen through the development process. So who knows Bayer may be among the first major pharmaceutical companies getting involved in transgenically derived products.
Market Data 
Markets 
AI
